Fc containing polypeptides with altered glycosylation and reduced effector function

Patent metadata

Field	Value
Publication number	US-9790268-B2
Application number	US-201414205264-A
Country	US
Kind code	B2
Filing date	Mar 11, 2014
Priority date	Sep 12, 2012
Publication date	Oct 17, 2017
Grant date	Oct 17, 2017

Abstract

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

First claim

We claim:

1. An isolated binding polypeptide comprising an Fc domain, wherein the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering, and wherein the binding polypeptide has a lower affinity for an Fcγ receptor than a binding polypeptide having a native Fc domain.

2. The binding polypeptide of claim 1 , further comprising an alanine residue at amino acid position 299, according to EU numbering.

3. The binding polypeptide of claim 1 , further comprising a glutamine residue at amino acid position 297, according to EU numbering.

4. The binding polypeptide of claim 1 , wherein the Fc domain is an IgG1 Fc domain.

5. The binding polypeptide of claim 1 , wherein the Fc domain is human.

6. The binding polypeptide of claim 1 , wherein the side chain of the asparagine residue is linked to a glycan though a β-glycosylamide linkage.

7. The binding polypeptide of claim 6 , wherein the glycan is a biantennary glycan.

8. The binding polypeptide of claim 6 , wherein the glycan is a naturally occurring mammalian glycoform.

9. The binding polypeptide of claim 1 , wherein the Fcγ receptor is FcγRI and/or FcγRIIIa.

10. The binding polypeptide of claim 1 which has a similar affinity for an FcRn receptor as a binding polypeptide having a native Fc domain.

11. The binding polypeptide of claim 6 , wherein the glycan comprises a reactive aldehyde group.

12. The binding polypeptide of claim 6 , wherein the glycan comprises an oxidized saccharide residue comprising a reactive aldehyde group.

13. The binding polypeptide of claim 12 , wherein the oxidized saccharide residue is a terminal sialic acid or galactose.

14. The binding polypeptide of claim 6 , wherein the glycan is linked to an effector moiety.

15. The binding polypeptide of claim 14 , wherein the effector moiety is a cytotoxin or a detection agent.

16. The binding polypeptide of claim 14 , wherein the effector moiety comprises a pH-sensitive linker, disulfide linker, enzyme-sensitive linker or other cleavable linker moiety.

17. The binding polypeptide of claim 1 which is an antibody.

18. An isolated binding polypeptide comprising an Fc domain, wherein the Fc domain comprises: a free asparagine residue at amino acid position 298, according to EU numbering; and a free serine or threonine residue at amino acid position 300, according to EU numbering.

19. An isolated binding polypeptide comprising an Fc domain, wherein the Fc domain comprises: an N-glycan linked to an asparagine residue at amino acid position 298, according to EU numbering; and a free serine or threonine residue at amino acid position 300, according to EU numbering.

20. The binding polypeptide of claim 19 , wherein an effector moiety is linked through a side chain of the asparagine residue to a saccharide residue of the N-glycan.

21. The binding polypeptide of claim 20 , wherein the saccharide residue is a terminal sialic acid or galactose residue.

22. The binding polypeptide of claim 19 , which is an antibody, and wherein the N-glycan is linked to a drug effector moiety to form an antibody drug conjugate (ADC).

23. A composition comprising a binding polypeptide of claim 1 and a pharmaceutically acceptable carrier or excipient.

24. The binding polypeptide of claim 1 which is an immunoadhesin comprising a non-antibody binding region.

25. The binding polypeptide of claim 24 , wherein the non-antibody binding region is a receptor.

26. The binding polypeptide of claim 24 , wherein the non-antibody binding region is a ligand of a receptor.

27. The binding polypeptide of claim 1 , wherein the binding polypeptide comprises at least one binding site which is a ligand binding site of a receptor.

28. The binding polypeptide of claim 1 , wherein the binding polypeptide comprises at least one binding site which is a receptor binding site of a ligand.

29. The binding polypeptide of claim 19 , which is an antibody.

30. The binding polypeptide of claim 19 , which is an immunoadhesin comprising a non-antibody binding region.

31. The binding polypeptide of claim 30 , wherein the non-antibody binding region is a receptor.

32. The binding polypeptide of claim 30 , wherein the non-antibody binding region is a ligand of a receptor.

33. The binding polypeptide of claim 19 , wherein the binding polypeptide comprises at least one binding site which is a ligand binding site of a receptor.

34. The binding polypeptide of claim 19 , wherein the binding polypeptide comprises at least one binding site which is a receptor binding site of a ligand.

35. An isolated binding polypeptide comprising a human IgG1 Fc domain, wherein the Fc domain comprises: an asparagine residue at amino acid position 297, according to EU numbering; a glycosylated asparagine residue at amino acid position 298, according to EU numbering; an amino acid at position 299, according to EU numbering, wherein said amino acid at position 299 is not proline; and a serine or threonine residue at amino acid position 300, according to EU numbering.

36. An isolated binding polypeptide comprising a human IgG1 Fc domain, wherein the Fc domain comprises: an glutamine residue at amino acid position 297, according to EU numbering; a glycosylated asparagine residue at amino acid position 298, according to EU numbering; an amino acid at position 299, according to EU numbering, wherein said amino acid at position 299 is not proline; and a serine or threonine residue at amino acid position 300, according to EU numbering.

37. An isolated binding polypeptide comprising a human IgG1 Fc domain, wherein the Fc domain comprises: an asparagine residue at amino acid position 297, according to EU numbering; a glycosylated asparagine residue at amino acid position 298, according to EU numbering; an alanine residue at amino acid position 299, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering.

38. An isolated binding polypeptide comprising a human IgG4 Fc domain, wherein the Fc domain comprises: a glycosylated asparagine residue at amino acid position 298, according to EU numbering; an alanine residue at amino acid position 299, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering.

39. The isolated binding polypeptide of claim 38 , wherein the Fc domain comprises a hinge region with a Ser228Pro mutation (EU numbering).

Assignees

• Genzyme Corp

Inventors

• Pan Clark
• Qiu Huawei

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61K47/48384

  Human Necessities · mapped topic

• A61K49/0004

  Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title

• A61K47/68031

  the drug being an auristatin · CPC title